Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Aug;87(16):6136–6140. doi: 10.1073/pnas.87.16.6136

Priming of CD4+ T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp120 in humans immunized with a recombinant envelope protein.

S Abrignani 1, D Montagna 1, M Jeannet 1, J Wintsch 1, N L Haigwood 1, J R Shuster 1, K S Steimer 1, A Cruchaud 1, T Staehelin 1
PMCID: PMC54487  PMID: 1696717

Abstract

A nonglycosylated denatured form of human immunodeficiency virus (HIV) 1 glycoprotein gp120 (Env 2-3), which does not bind to CD4, was used with muramyl tripeptide as adjuvant to immunize HIV-seronegative healthy volunteers. In all the volunteers, three 50-micrograms injections of Env 2-3 induced priming of CD4+ T cells specific for conserved regions of the native glycosylated gp120. Moreover, we found that several major histocompatibility complex class II (DR) alleles can function as restriction molecules for presentation of conserved epitopes of gp120 to T cells, implying that a T-cell response to these epitopes can be obtained in a large fraction of the population. The possibility to prime CD4+ T cells specific for conserved epitopes of a HIV protein is particularly important in view of the lack of such cells in HIV-infected individuals and of a possible role that CD4+ T cells may play in the development of protective immunity against AIDS.

Full text

PDF
6136

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barr P. J., Steimer K. S., Sabin E. A., Parkes D., George-Nascimento C., Stephans J. C., Powers M. A., Gyenes A., Van Nest G. A., Miller E. T. Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae. Vaccine. 1987 Jun;5(2):90–101. doi: 10.1016/0264-410x(87)90053-3. [DOI] [PubMed] [Google Scholar]
  2. Gurley R. J., Ikeuchi K., Byrn R. A., Anderson K., Groopman J. E. CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1993–1997. doi: 10.1073/pnas.86.6.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Krowka J. F., Stites D. P., Jain S., Steimer K. S., George-Nascimento C., Gyenes A., Barr P. J., Hollander H., Moss A. R., Homsy J. M. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest. 1989 Apr;83(4):1198–1203. doi: 10.1172/JCI114001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985 Apr 11;314(6011):537–539. doi: 10.1038/314537a0. [DOI] [PubMed] [Google Scholar]
  5. Lanzavecchia A., Roosnek E., Gregory T., Berman P., Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature. 1988 Aug 11;334(6182):530–532. doi: 10.1038/334530a0. [DOI] [PubMed] [Google Scholar]
  6. Lasky L. A., Nakamura G., Smith D. H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D. J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987 Sep 11;50(6):975–985. doi: 10.1016/0092-8674(87)90524-1. [DOI] [PubMed] [Google Scholar]
  7. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 Dec;19(12):2237–2242. doi: 10.1002/eji.1830191209. [DOI] [PubMed] [Google Scholar]
  8. Plata F., Autran B., Martins L. P., Wain-Hobson S., Raphaël M., Mayaud C., Denis M., Guillon J. M., Debré P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987 Jul 23;328(6128):348–351. doi: 10.1038/328348a0. [DOI] [PubMed] [Google Scholar]
  9. Prince A. M., Pascual D., Kosolapov L. B., Kurokawa D., Baker L., Rubinstein P. Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis. 1987 Aug;156(2):268–272. doi: 10.1093/infdis/156.2.268. [DOI] [PubMed] [Google Scholar]
  10. Ranki A., Mattinen S., Yarchoan R., Broder S., Ghrayeb J., Lähdevirta J., Krohn K. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS. 1989 Feb;3(2):63–69. doi: 10.1097/00002030-198902000-00002. [DOI] [PubMed] [Google Scholar]
  11. Sanchez-Pescador L., Burke R. L., Ott G., Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol. 1988 Sep 1;141(5):1720–1727. [PubMed] [Google Scholar]
  12. Sattentau Q. J., Weiss R. A. The CD4 antigen: physiological ligand and HIV receptor. Cell. 1988 Mar 11;52(5):631–633. doi: 10.1016/0092-8674(88)90397-2. [DOI] [PubMed] [Google Scholar]
  13. Siliciano R. F., Lawton T., Knall C., Karr R. W., Berman P., Gregory T., Reinherz E. L. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell. 1988 Aug 12;54(4):561–575. doi: 10.1016/0092-8674(88)90078-5. [DOI] [PubMed] [Google Scholar]
  14. Sprent J., Webb S. R. Function and specificity of T cell subsets in the mouse. Adv Immunol. 1987;41:39–133. doi: 10.1016/s0065-2776(08)60030-9. [DOI] [PubMed] [Google Scholar]
  15. Srinivasan A., Anand R., York D., Ranganathan P., Feorino P., Schochetman G., Curran J., Kalyanaraman V. S., Luciw P. A., Sanchez-Pescador R. Molecular characterization of human immunodeficiency virus from Zaire: nucleotide sequence analysis identifies conserved and variable domains in the envelope gene. Gene. 1987;52(1):71–82. doi: 10.1016/0378-1119(87)90396-9. [DOI] [PubMed] [Google Scholar]
  16. Starcich B. R., Hahn B. H., Shaw G. M., McNeely P. D., Modrow S., Wolf H., Parks E. S., Parks W. P., Josephs S. F., Gallo R. C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. doi: 10.1016/0092-8674(86)90778-6. [DOI] [PubMed] [Google Scholar]
  17. Wahren B., Morfeldt-Månsson L., Biberfeld G., Moberg L., Ljungman P., Nordlund S., Bredberg-Rådén U., Werner A., Löwer J., Kurth R. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med. 1986 Aug 7;315(6):393–394. [PubMed] [Google Scholar]
  18. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  19. Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985 Jul 4;316(6023):69–72. doi: 10.1038/316069a0. [DOI] [PubMed] [Google Scholar]
  20. Willey R. L., Rutledge R. A., Dias S., Folks T., Theodore T., Buckler C. E., Martin M. A. Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5038–5042. doi: 10.1073/pnas.83.14.5038. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES